Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Teratogenicity01:07

Teratogenicity

4.2K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.2K
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

658
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
658
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

388
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
388
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

252
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
252
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

975
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
975

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Use, Prescribing Patterns, and Short-Term Clinical Evolution of Extensively Hydrolyzed and Hydrolyzed Rice Formulas in Infants with Cow's Milk Protein Allergy: An Analysis from the ETAPA Project.

Nutrients·2026
Same author

Patterns of Ultra-Processed Food Consumption in a Gluten-Free Diet: A Target for Nutritional Intervention.

Nutrients·2026
Same author

Bridging Rare to Common Diseases: Precision Medicine and the Transforming Landscape of Pediatric Allergy and Immunology.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2026
Same author

Longitudinal Follow-Up of Gut and Salivary Microbiota in Children With Food Protein-Induced Enterocolitis Syndrome.

Allergy·2026
Same author

Fatigue in pediatric patients with inflammatory bowel disease: a multicenter study by the SEGHNP.

Crohn's & colitis 360·2026
Same author

Preparedness and performance in pediatric assessment: linking OSCE, written exams, and training exposure in a two-year comparative study of medical students.

BMC medical education·2026

Related Experiment Video

Updated: May 6, 2026

Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation
09:02

Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation

Published on: February 15, 2018

19.4K

Growth, Safety and Tolerance in Infants Fed Rice Protein Hydrolysate Formula: The GRITO Randomised Controlled Trial.

Anaïs Lemoine1, Antonio Nieto-García2, María Nieto-Cid2

  • 1Service de Nutrition et Gastro-Entérologie Pédiatrique, Hôpital Armand Trousseau AP HP, Sorbonne Université, 75571 Paris, France.

Nutrients
|January 11, 2025
PubMed
Summary

Hydrolysed rice formula (HRF) supports appropriate growth and tolerance acquisition in infants with cow's milk protein allergy (CMPA), showing comparable safety and efficacy to extensively hydrolysed formula (eHF).

Keywords:
arsenicchildrencow’s milk protein allergyhydrolysed rice-based formulatolerance

More Related Videos

Probiotic Studies in Neonatal Mice Using Gavage
10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

19.3K
Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
09:36

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers

Published on: July 28, 2022

2.2K

Related Experiment Videos

Last Updated: May 6, 2026

Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation
09:02

Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation

Published on: February 15, 2018

19.4K
Probiotic Studies in Neonatal Mice Using Gavage
10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

19.3K
Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
09:36

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers

Published on: July 28, 2022

2.2K

Area of Science:

  • Pediatric Nutrition
  • Allergy and Immunology
  • Gastroenterology

Background:

  • Cow's milk protein allergy (CMPA) affects a significant number of infants.
  • Hydrolysed rice formula (HRF) is a common alternative, but growth concerns exist compared to extensively hydrolysed formula (eHF).

Purpose of the Study:

  • To compare the growth, safety, and tolerance acquisition in infants diagnosed with CMPA when fed either HRF or eHF.
  • To evaluate anthropometric measurements and adverse events in infants with CMPA on different formulas.

Main Methods:

  • A multicentre, prospective, randomized, double-blind, placebo-controlled trial.
  • 105 infants with CMPA were randomized to receive either HRF or eHF for 12 months.
  • Primary outcome: change in weight-for-length Z-score; secondary outcomes: anthropometrics, tolerability, adverse events.

Main Results:

  • No significant differences in weight-for-length Z-scores between HRF and eHF groups (p=0.28).
  • Normal growth patterns observed across all anthropometric variables in both groups.
  • Similar safety profiles and tolerability, with a trend towards faster tolerance acquisition in the HRF group.

Conclusions:

  • HRF is a safe and effective option for managing CMPA, supporting appropriate growth and tolerance development.
  • HRF demonstrates comparable outcomes to eHF in infants with CMPA.
  • HRF can be considered a suitable alternative in CMPA management.